A new study is showing that the new class of weight loss drugs like Ozempic and Wegovy may help lower the risk of 10 different obesity-related cancers. Dr. Roshini Raj joins TODAY to break down the findings.
Younger generations have a heightened risk of some cancers, new research found. A study published Wednesday in Lancet Public Health found that Gen X and millennials are more likely to be diagnosed with 17 types of cancer, including nine that had been declining in older adults. Researchers aren’t sure why, but say obesity is likely a leading cause.
“That was a sobering finding,” said Sung. “Although many cancer rates are rising, we don’t necessarily see this increase in mortality because we are treating them a lot better than before.” Many of the cancers found to be on the rise are still rare in young people and, while rates have increased, the overall number of cases is comparatively low. “It is clearly happening.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozempic And Wegovy Could Help Smokers Quit, Study SuggestsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss DrugsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss DrugsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Only 1 in 4 Still Taking Ozempic, Wegovy for Weight Loss Two Years LaterThree of four patients stop taking Ozempic or Wegovy two years after being prescribed the blockbuster drugs for weight loss, a new analysis shows.
Read more »
No More Nausea: New Discovery Could Reduce the Side Effects of Ozempic and WegovyScience, Space and Technology News 2024
Read more »
Most Patients Stop Using Wegovy, Ozempic for Weight Loss Within Two Years, Analysis FindsOnly one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular medications two years later, according to an...
Read more »